Péptido Retatrutida 5 mg/vial 10 mg/vial
investigación- Descripción
retatrutida (LY3437943) es un agonista del polipéptido insulinotrópico dependiente de glucosa, péptido similar al glucagón 1, y receptores de glucagón. Sus relaciones dosis-respuesta con respecto a los efectos secundarios., seguridad, y se desconoce su eficacia para el tratamiento de la obesidad.
Methods
We conducted a phase 2, doble ciego, aleatorio, placebo-controlled trial involving adults who had a body-mass index (BMI, the weight in kilograms divided by the square of the height in meters) de 30 or higher or who had a BMI of 27 to less than 30 plus at least one weight-related condition. Participants were randomly assigned in a 2:1:1:1:1:2:2 ratio to receive subcutaneous retatrutide (1 mg, 4 mg [initial dose, 2 mg], 4 mg [initial dose, 4 mg], 8 mg [initial dose, 2 mg], 8 mg [initial dose, 4 mg], or 12 mg [initial dose, 2 mg]) or placebo once weekly for 48 semanas. The primary end point was the percentage change in body weight from baseline to 24 semanas. Secondary end points included the percentage change in body weight from baseline to 48 weeks and a weight reduction of 5% o más, 10% o más, or 15% o más. Safety was also assessed.
Conclusions
In adults with obesity, retatrutide treatment for 48 weeks resulted in substantial reductions in body weight.
Péptidos retatrutida, Tirzepatide, tirzepatide weight loss, monjaro, tirzepatide cost, tirzepatide online, tirzepatide injections, mounjaro 5mg, tirzepatide for weight loss, mounjaro injection
ENVIAR CONSULTA
Productos relacionados
© rawsteroidpowder.com 2024. Reservados todos los derechos
Desarrollado por wpboss
Servicio
Telegrama：Anabolicraws
Signal:Anabolicraws.11
